N2off signs definitive agreement to acquire next-gen computational drug discovery company, targeting hard to treat cancers

Neve yarak, israel, feb. 26, 2025 (globe newswire) -- n2off, inc.\ (nasdaq: nito) (fse:80w) (“n2off” and the “company”), a clean tech company engaged in sustainable solutions for solar energy, energy battery storage and innovation for agri- tech, announced today that it has entered a definitive agreement to acquire mitocarex bio ltd. ("mitocarex"), a biotech company focused on drug discovery targeting cancer therapeutics, with a range of other potential diseases and disorders, through targeting the mitochondrial slc25 protein family.
NITO Ratings Summary
NITO Quant Ranking